{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:11:44Z","timestamp":1790518304108,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40261-020-00980-w","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T09:03:38Z","timestamp":1603357418000},"page":"1177-1181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors"],"prefix":"10.1007","volume":"40","author":[{"given":"Alessandra","family":"Serrao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Scalzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Di Prima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2593-1376","authenticated-orcid":false,"given":"Antonio","family":"Chistolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"issue":"14","key":"980_CR1","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","volume":"344","author":"J Goldman","year":"2001","unstructured":"Goldman J, Melo J. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1084\u20136.","journal-title":"N Engl J Med"},{"issue":"6","key":"980_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","volume":"3","author":"P Jain","year":"2019","unstructured":"Jain P, Kantarjian H, Boddu PC, Nogueras-Gonz\u00e1lez GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O\u2019Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontlineTKIs. Blood Adv. 2019;3(6):851\u201361.","journal-title":"Blood Adv."},{"issue":"1","key":"980_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","volume":"16","author":"H Haguet","year":"2017","unstructured":"Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogn\u00e8 JM. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017;16(1):5\u201312.","journal-title":"Expert Opin Drug Saf."},{"issue":"3","key":"980_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/M15-2306","volume":"165","author":"T Dahl\u00e8n","year":"2016","unstructured":"Dahl\u00e8n T, Edgren G, Lambe M, Swedish CML Group and the Swedish CML Register Group, et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med. 2016;165(3):161\u20136.","journal-title":"Ann Intern Med."},{"issue":"5","key":"980_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"JT Hartmann","year":"2009","unstructured":"Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors\u2014a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10(5):470\u201381.","journal-title":"Curr Drug Metab."},{"issue":"2","key":"980_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315\u201352.","journal-title":"Chest"},{"issue":"8","key":"980_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/europace\/euy054","volume":"20","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Georg Haeusler K, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidb\u00fcchel H, ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;20(8):1231\u201342.","journal-title":"Europace."},{"key":"980_CR8","unstructured":"Drug Interactions & Labelling. Drug development and drug interactions: table of substrates, inhibitors and inducers, www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/druginteractionslabeling\/ucm093664.htm. Accessed 10 Dec 2018."},{"issue":"1","key":"980_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","volume":"151","author":"BT Samuelson","year":"2017","unstructured":"Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest. 2017;151(1):127\u201338.","journal-title":"Chest"},{"issue":"6","key":"980_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691\u2013709.","journal-title":"Am J Hematol"},{"key":"980_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","volume":"2","author":"J Douxfils","year":"2016","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogne JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2:625\u201332.","journal-title":"JAMA Oncol."},{"issue":"11","key":"980_CR12","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1177\/1060028013504741","volume":"47","author":"T Hellwig","year":"2013","unstructured":"Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother. 2013;47(11):1478\u201387","journal-title":"Ann Pharmacother"},{"key":"980_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/2042098617719815","volume":"8","author":"HL Forbes","year":"2017","unstructured":"Forbes HL, Polasek TM. Potential drug\u2013drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Saf. 2017;8:319\u201328.","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"980_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","volume":"19","author":"NJ Short","year":"2014","unstructured":"Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist. 2014;19(1):82\u201393.","journal-title":"Oncologist"},{"issue":"2","key":"980_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","volume":"114","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114(2):261\u20133.","journal-title":"Blood"},{"key":"980_CR16","doi-asserted-by":"crossref","first-page":"107602962093632","DOI":"10.1177\/1076029620936325","volume":"26","author":"P\u00c9JF de Miranda","year":"2020","unstructured":"de Miranda P\u00c9JF, Takahashi T, Iwamoto F, et al. Drug-drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: a comprehensive review of interactions and mechanisms. Clin Appl Thromb Hemost. 2020;26:1076029620936325.","journal-title":"Clin Appl Thromb Hemost."},{"issue":"7","key":"980_CR17","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/jth.14457","volume":"17","author":"S Testa","year":"2019","unstructured":"Testa S, Legnani C, Antonucci E, et al. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2019;17(7):1064\u201372.","journal-title":"J Thromb Haemost."},{"issue":"12","key":"980_CR18","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1080\/10428194.2017.1315115","volume":"58","author":"KL Chai","year":"2017","unstructured":"Chai KL, Rowan G, Seymour JF, Burbury K, Carney D, Tam CS. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leuk Lymph. 2017;58(12):2811\u20134.","journal-title":"Leuk Lymph."},{"issue":"1","key":"980_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00228-016-2115-0","volume":"73","author":"PH Hsyu","year":"2017","unstructured":"Hsyu PH, Pignataro DS, Matschke K. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. Eur J Clin Pharmacol. 2017;73(1):57\u201363.","journal-title":"Eur J Clin Pharmacol."},{"issue":"Supplement 1","key":"980_CR20","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1182\/blood-2018-99-114234","volume":"132","author":"EP Deloughery","year":"2018","unstructured":"Deloughery EP, McBane RD, Ashrani AA, et al. Direct oral anticoagulants in patients with myeloproliferative neoplasms: a single institution retrospective study. Blood. 2018;132(Supplement 1):5067.","journal-title":"Blood"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00980-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T23:45:45Z","timestamp":1634859945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00980-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["980"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00980-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"10 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was not supported by any funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors do not have any potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This was a retrospective study and our institutional ethics committee waived formal assessment of the protocol.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"According to institutional procedures all the patients signed informed consent to therapies and to the use of their data for scientific purposes.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}